Actively Recruiting
Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms
Led by Penang Hospital, Malaysia · Updated on 2025-09-05
150
Participants Needed
2
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to compare how well Terazosin, Tamsulosin and standard care (no alpha-blocker) reduce urinary symptoms after ureteral stent placement. This trial also learn about the safety of these two study medications. Main objective: • To compare how well Terazosin, Tamsulosin and standard of care reduce post-stenting urinary symptoms. Secondary objectives: * To compare painkiller use among the groups. * To assess differences in Body pain, General health, Work performance, Sexual matters, and Additional problems using a questionnaire (USSQ). * To assess differences in side effects. After stent placement, subjects will be randomly assigned to one of three groups: 1. Terazosin (alpha-blocker) for 14 days 2. Tamsulosin (alpha-blocker) for 14 days 3. Standard of care (no alpha-blocker). All subjects will be discharged with standard pain-killers and a diary to track usage. Subjects in Terazosin and Tamsulosin groups will receive respective study medications to complete 14 days course of treatment. Follow-Up: * Day 7: A phone call will check medication use and any side effects. * Day 15: Clinic visit for stent removal (standard practice). Subjects will complete the USSQ questionnaire, and medication compliance will be reviewed. End of study: Final phone call to check for any additional side effects.
CONDITIONS
Official Title
Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Malaysian age 18 years old and above
- Able to provide written informed consent to participate in the trial
- Willing to comply with study procedures
- Undergoing unilateral intracorporeal lithotripsy with ureteral stent placement for uncomplicated ureteric or renal stones
You will not qualify if you...
- Known comorbidities increasing risk of complications including prostate pathology (benign prostatic hyperplasia, prostatitis, prostatic carcinoma)
- Bladder pathology such as bladder tumor, stone, or overactive bladder
- Ureteral abnormalities, trauma, or urethral stricture
- Concomitant urinary tract infection
- Orthostatic hypotension
- Solitary kidney
- Previous pelvic or gynecological surgery
- Receiving chronic pain treatment from a pain clinic
- Pregnancy for women of childbearing potential
- Known allergic reactions to tamsulosin or terazosin
- Taking warfarin or H2 receptor blockers
- Any clinical conditions judged unsuitable by researchers or clinicians
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sultanah Bahiyah Hospital, Alor Setar
Alor Star, Kedah, Malaysia, 05460
Actively Recruiting
2
Hospital Pulau Pinang
George Town, Pulau Pinang, Malaysia, 10450
Actively Recruiting
Research Team
Y
Yeon Wee Ooi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here